dc.identifier.uri |
http://dx.doi.org/10.15488/1399 |
|
dc.identifier.uri |
http://www.repo.uni-hannover.de/handle/123456789/1424 |
|
dc.contributor.author |
Worthmann, Hans
|
|
dc.contributor.author |
Dengler, Reinhard
|
|
dc.contributor.author |
Schumacher, Helmut
|
|
dc.contributor.author |
Schwartz, Andreas
|
|
dc.contributor.author |
Eisert, Wolfgang G.
|
|
dc.contributor.author |
Lichtinghagen, Ralf
|
|
dc.contributor.author |
Weissenborn, Karin
|
|
dc.date.accessioned |
2017-04-21T12:00:25Z |
|
dc.date.available |
2017-04-21T12:00:25Z |
|
dc.date.issued |
2012 |
|
dc.identifier.citation |
Worthmann, H.; Dengler, R.; Schumacher, H.; Schwartz, A.; Eisert, W.G. et al.: Monocyte chemotactic protein-1 as a potential biomarker for early anti-thrombotic therapy after ischemic stroke. In: International Journal of Molecular Sciences 13 (2012), Nr. 7, S. 8670-8678. DOI: https://doi.org/10.3390/ijms13078670 |
|
dc.description.abstract |
Inflammation following ischemic brain injury is correlated with adverse outcome. Preclinical studies indicate that treatment with acetylsalicylic acid + extended-release dipyridamole (ASA + ER-DP) has anti-inflammatory and thereby neuroprotective effects by inhibition of monocyte chemotactic protein-1 (MCP-1) expression. We hypothesized that early treatment with ASA + ER-DP will reduce levels of MCP-1 also in patients with ischemic stroke. The EARLY trial randomized patients with ischemic stroke or TIA to either ASA + ER-DP treatment or ASA monotherapy within 24 h following the event. After 7 days, all patients were treated for up to 90 days with ASA + ER-DP. MCP-1 was determined from blood samples taken from 425 patients on admission and day 8. The change in MCP-1 from admission to day 8 did not differ between patients treated with ASA + ER-DP and ASA monotherapy (p > 0.05). Comparisons within MCP-1 baseline quartiles indicated that patients in the highest quartile (> 217-973 pg/mL) showed improved outcome at 90 days if treated with ASA + ER-DP in comparison to treatment with ASA alone (p = 0.004). Our data does not provide any evidence that treatment with ASA + ER-DP lowers MCP-1 in acute stroke patients. However, MCP-1 may be a useful biomarker for deciding on early stroke therapy, as patients with high MCP-1 at baseline appear to benefit from early treatment with ASA + ER-DP. |
eng |
dc.language.iso |
eng |
|
dc.publisher |
Basel : MDPI AG |
|
dc.relation.ispartofseries |
International Journal of Molecular Sciences 13 (2012), Nr. 7 |
|
dc.rights |
CC BY-NC-SA 3.0 Unported |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-sa/3.0/ |
|
dc.subject |
Acetylsalicylic acid (ASA) |
eng |
dc.subject |
Antithrombotic therapy |
eng |
dc.subject |
Dipyridamole |
eng |
dc.subject |
Ischemic stroke |
eng |
dc.subject |
Monocyte chemoattractant protein-1 (MCP-1) |
eng |
dc.subject |
Neuroprotection |
eng |
dc.subject |
acetylsalicylic acid |
eng |
dc.subject |
dipyridamole |
eng |
dc.subject |
monocyte chemotactic protein 1 |
eng |
dc.subject |
acetylsalicylic acid |
eng |
dc.subject |
antithrombocytic agent |
eng |
dc.subject |
biological marker |
eng |
dc.subject |
CCL2 protein, human |
eng |
dc.subject |
dipyridamole |
eng |
dc.subject |
monocyte chemotactic protein 1 |
eng |
dc.subject |
adult |
eng |
dc.subject |
aged |
eng |
dc.subject |
article |
eng |
dc.subject |
brain ischemia |
eng |
dc.subject |
controlled study |
eng |
dc.subject |
disease severity |
eng |
dc.subject |
early intervention |
eng |
dc.subject |
female |
eng |
dc.subject |
human |
eng |
dc.subject |
major clinical study |
eng |
dc.subject |
male |
eng |
dc.subject |
monotherapy |
eng |
dc.subject |
multicenter study |
eng |
dc.subject |
National Institutes of Health Stroke Scale |
eng |
dc.subject |
open study |
eng |
dc.subject |
predictive value |
eng |
dc.subject |
prognosis |
eng |
dc.subject |
protein blood level |
eng |
dc.subject |
randomized controlled trial |
eng |
dc.subject |
transient ischemic attack |
eng |
dc.subject |
blood |
eng |
dc.subject |
drug combination |
eng |
dc.subject |
follow up |
eng |
dc.subject |
middle aged |
eng |
dc.subject |
Stroke |
eng |
dc.subject |
time |
eng |
dc.subject |
very elderly |
eng |
dc.subject |
Adult |
eng |
dc.subject |
Aged |
eng |
dc.subject |
Aged, 80 and over |
eng |
dc.subject |
Aspirin |
eng |
dc.subject |
Biological Markers |
eng |
dc.subject |
Brain Ischemia |
eng |
dc.subject |
Chemokine CCL2 |
eng |
dc.subject |
Dipyridamole |
eng |
dc.subject |
Drug Therapy, Combination |
eng |
dc.subject |
Female |
eng |
dc.subject |
Follow-Up Studies |
eng |
dc.subject |
Humans |
eng |
dc.subject |
Male |
eng |
dc.subject |
Middle Aged |
eng |
dc.subject |
Platelet Aggregation Inhibitors |
eng |
dc.subject |
Stroke |
eng |
dc.subject |
Time Factors |
eng |
dc.subject.ddc |
540 | Chemie
|
ger |
dc.subject.ddc |
570 | Biowissenschaften, Biologie
|
ger |
dc.title |
Monocyte chemotactic protein-1 as a potential biomarker for early anti-thrombotic therapy after ischemic stroke |
|
dc.type |
Article |
|
dc.type |
Text |
|
dc.relation.essn |
1422-0067 |
|
dc.relation.issn |
1661-6596 |
|
dc.relation.doi |
https://doi.org/10.3390/ijms13078670 |
|
dc.bibliographicCitation.issue |
7 |
|
dc.bibliographicCitation.volume |
13 |
|
dc.bibliographicCitation.firstPage |
8670 |
|
dc.bibliographicCitation.lastPage |
8678 |
|
dc.description.version |
publishedVersion |
|
tib.accessRights |
frei zug�nglich |
|